SPL 4.00% 12.0¢ starpharma holdings limited

Starpharma (SPL) reported that AstraZeneca has commenced a phase...

  1. 824 Posts.
    lightbulb Created with Sketch. 44
    Starpharma (SPL) reported that AstraZeneca has commenced a phase 1 clinical trial of AZD0466 (DEP Bcl2/xL conjugate) and the first patient has been successfully dosed. The development of AZD0466, is being progressed under a multi-product license whereby Starpharma is eligible to receive development, launch and sales milestones of up to US$124 million, plus tiered royalties on net sales. The first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million

    http://crweworld.com/article/news-provided-by-business-wire/1363908/starpharma-commencement-of-phase-1-trial-for-azd0466-utilising-dep-delivery-technology
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
12.0¢
Change
-0.005(4.00%)
Mkt cap ! $49.44M
Open High Low Value Volume
12.0¢ 12.5¢ 12.0¢ $34.86K 289.9K

Buyers (Bids)

No. Vol. Price($)
5 263226 12.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.5¢ 57773 3
View Market Depth
Last trade - 16.10pm 07/05/2024 (20 minute delay) ?
Last
12.5¢
  Change
-0.005 ( 4.17 %)
Open High Low Volume
12.0¢ 12.5¢ 12.0¢ 6229
Last updated 15.59pm 07/05/2024 ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.